Accession Number:

AD1191111

Title:

Making the CASE: Chemopreventive use of ASpirin for ovarian cancer- integrating Epidemiological data to evaluate population subgroups and tumor expression

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:

GENEVA FOUNDATION TACOMA WA

Personal Author(s):

• Trabert, Britton
• Trabert, Britton

Report Date:

2022-10-01

Pagination or Media Count:

16

Abstract:

We hypothesize that the use of updated exposure information in cohort analyses will clarify and refine the ovarian cancer risk reductionassociated with aspirin, that there are subgroups of women who will derive the most benefit from daily aspirin use with respect to ovarian cancerchemoprevention, and that aspirin will preferentially reduce risk for ovarian cancers dependent on the tumor immune microenvironment.Impact The proposed research directly addresses the OCRP vision to eliminate ovarian cancer, by addressing critical questions related to the preventionof ovarian cancer. This research also addresses OCRP research objectives related to cancer etiology, primary prevention, and understanding themechanisms by which aspirin can prevent ovarian cancer. By leveraging and expanding upon the OC3 infrastructure through collection of updatedexposure information and tumor tissue this well-powered investigation of aspirin use with ovarian cancer risk will address key questions needed to developrecommendations for aspirin-based chemoprevention.

Descriptors:

• risk
• epidemiology
• medical personnel
• neoplasms
• public health
• cancer
• data analysis
• health
• risk reduction
• drug therapy
• ovarian cancer
• risk factors
• side effects
• abstracts
• ligation
• statistical analysis
• biomedical research

Subject Categories:

Distribution Statement:

[A, Approved For Public Release]